By Fineline Cube 
China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s PT Ferron Par Pharmaceuticals for its core eye‑drop, BRIMOCHOL PF. The deal grants PT Ferron exclusive import, promotion and retail rights for the product across Indonesia, with Zhaoke to receive an upfront fee and milestone‑based payments contingent on market performance.
Agreement Highlights
- Exclusive Distribution – PT Ferron Par receives sole rights to import, promote, distribute, market and sell BRIMOCHOL PF in Indonesia.
- Financial Structure – Zhaoke will receive an upfront transfer fee plus future milestone payments tied to predefined performance criteria (e.g., sales thresholds, registration milestones).
- Strategic Alignment – The partnership leverages Ferron’s established Indonesian supply chain and Zhaoke’s clinical expertise in presbyopia treatment.
BRIMOCHOL PF – Product Snapshot
| Feature | Detail |
|---|---|
| Indication | Once‑daily eye drop for presbyopia (age‑related near‑vision blur). |
| Fixed‑Dose Combination | Miotic carbachol + α₂‑agonist brimonidine. |
| Development Rights | Zhaoke secured commercialization rights in Greater China, South Korea and select Southeast Asian markets in May 2022 from Visus Therapeutics, Inc. |
| Regulatory Progress | FDA NDA accepted (June 2025) with PDUFA date Jan 28 2026; the product entered the U.S. market via a 2024 merger with Tenpoint Therapeutics Ltd. |
Market Implications
- Rapid Penetration – PT Ferron’s nationwide distribution network provides a ready platform for introducing an innovative, once‑daily presbyopia treatment to the growing Indonesian ophthalmic market, estimated to generate strong incremental revenue for Zhaoke.
- Milestone Growth – The structured payment schedule aligns Zhaoke’s upside with both regulatory milestones and commercial performance, potentially enhancing its valuation profile.
- Strategic Portfolio Expansion – The deal complements Zhaoke’s existing Greater China and South‑Korea presence, positioning the firm as a regional leader in vision‑care therapeutics.
Forward‑Looking Statements
This brief contains forward‑looking statements concerning the partnership, financial expectations, and regulatory milestones. Actual results may differ materially from those expressed herein due to market competition, regulatory changes, and other risks.-Fineline Info & Tech